Valeant's Hostile Bid For Cephalon
Valeant's hostile bid for Cephalon is a rejection of the traditional high risk, high reward R&D model employed by biopharma.
Valeant's hostile bid for Cephalon is a rejection of the traditional high risk, high reward R&D model employed by biopharma.